Navigation Links
Cardinal Health Announces Early Tender Results of Debt Tender Offer
Date:9/11/2009

DUBLIN, Ohio, Sept. 11 /PRNewswire-FirstCall/ -- Cardinal Health today announced the results of its early tender offer in connection with the offer to purchase up to an aggregate purchase price of $1.2 billion of its long-term debt securities.

The tender offer is part of a previously announced plan to reduce the company's long-term debt after the completion of the planned spinoff of CareFusion Corp. and includes notes issued by both Cardinal Health and one of its wholly owned subsidiaries, Allegiance Corp. After the close of business on Aug. 31, Cardinal Health completed the spinoff of CareFusion and received a cash distribution from CareFusion of approximately $1.4 billion.

Early Tender Results

As of 5 p.m., New York City time, on Thursday, Sept. 10, 2009 (the "early tender time"), the principal amounts of notes included in the table below have been tendered and not validly withdrawn, as reported by the tender agent:

                                                                     Principal
                                                                       Amount
                                                                      Tendered
                                                                       as of
                                            Principal                  Early
                                              Amount                   Tender
                                            Outstanding   Acceptance  Time (in
                       CUSIP/ISIN   Issuer (in millions)   Priority  millions)
          Notes          Number       (1)      (2)          Level        (3)

    7.80% Debentures    017475AB0;     A      $75.685           1     $31.450
     due Oct. 15, 2016 US017475AB07


    6.75% Notes due     14149YAF5;     C         $500           1    $279.781
     Feb. 15, 2011  
'/>"/>
SOURCE Cardinal Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Medical Technology Company CareFusion Spins Off From Cardinal Health, Begins Trading on NYSE
2. Cardinal Health Completes Spinoff of CareFusion Corp.
3. Cardinal Health Announces $1.2 Billion Debt Tender Offer
4. Cardinal Health Reports Fiscal 2009 Results, Provides Fiscal 2010 Outlook
5. George Barrett Named Chairman and CEO of Cardinal Health
6. NFL Cardinals Wide Receiver Larry Fitzgerald Promotes Vision Therapy
7. Cardinal Health Welcomes Record Number of Attendees at its Annual Independent Pharmacy Trade Show
8. Cardinal Health Announced as Title Sponsor of the Health Connect Partners 2009 Fall Hospital Pharmacy Conference
9. Cardinal Health Names Patricia Morrison Chief Information Officer
10. Cardinal Health Board of Directors Approves CareFusion Spinoff
11. Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... , , BRONX, N.Y., Aug. 3 ... raising their risk of bone and heart disease, according to a study ... striking findings suggest that vitamin D deficiency could place millions of children ... disease. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090803/DC55348 ...
... But another study finding suggests insulin treatment could boost ... Metformin, one of the most widely used diabetes drugs, ... odds for pancreatic cancer by 60 percent, a new ... Other common treatments, including the use of insulin or ...
... ER treatments since 1990 , SUNDAY, Aug. 2 (HealthDay News) ... climbing for fun and exercise, the number of injuries related ... study on the subject. , More than 40,000 people sought ... fractures, sprains and other ailments related to rock-climbing -- a ...
... ... be joining dental sleep medicine,s top sleep and dental sleep professionals at Somnomed,s first annual ... ... Isn,t Sexy, LLC will be joining dental sleep medicine,s top sleep and dental sleep professionals ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... , NASHVILLE, Tenn., Aug. 1 HCA Healthcare announces the following Webcast: , , ... Healthcare Webcast , , When: August ... http://www.videonewswire.com/event.asp?id=60459 , , How: ... the web at the address above. , , Contact: ...
Cached Medicine News:Health News:Millions Of U.S. Children Low In Vitamin D 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:Rock-Climbing Injury Rate Soaring 2Health News:Laurence I. Barsh, DMD, Founder of Snoring Isn't Sexy, to speak at Somnomed's First Annual Symposium 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: